Esomeprazole (Nexium)

DRUG4 trials

Sponsors

Douglas Trask, AstraZeneca, Meridian Bioscience, Inc.

Conditions

Erosive EsophagitisGastro-esophageal RefluxGastroesophageal Reflux Disease (GERD)Helicobacter Pylori InfectionNon-erosive Esophagitis

Phase 3

Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients

CompletedNCT00241501

AstraZenecaGastroesophageal Reflux Disease (GERD)

Start: 2004-02-29End: 2005-04-30Target: 140Updated: 2010-11-19

Phase 4

Esomeprazole for Treatment of GERD in Pediatric Patients

CompletedNCT00228527

AstraZenecaErosive Esophagitis, Gastroesophageal Reflux Disease (GERD), Non-erosive Esophagitis

Start: 2004-10-31End: 2005-10-31Target: 100Updated: 2010-11-19

13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)

CompletedNCT00825630

Meridian Bioscience, Inc.Helicobacter Pylori Infection

Start: 2008-11-30End: 2009-11-30Updated: 2022-12-20

Unknown Phase

Evaluation of Esomeprazole in Treating Gastro-esophageal Reflux Disease (GERD) in Head and Neck Cancer Patients Exposed to Radiation Therapy

TerminatedNCT00222079

Douglas TraskGastro-esophageal Reflux

Start: 2004-11-30End: 2008-02-29Updated: 2017-12-14

Related Papers

Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study.

2010-06-1119 citations

Effects of esomeprazole treatment for gastroesophageal reflux disease on quality of life in 12- to 17-year-old adolescents: an international health outcomes study.

2009-11-189 citations